Retrospective post hoc CV meta-analyses demonstrated that treatment with shorter-acting GLP-1 RAs (liraglutide or exenatide) did not increase the risk of MACE in patients with T2D [26, 27]. Here, GCG is linked to type 2 diabetes mellitus.